Kevin Heyries
Role: Associate
Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin
Stream: Advanced Therapies
Kevin Heyries is currently a business and strategy advisor working at the interface of science, innovation and investment with biotech, biopharma and VC groups.
Dr Heyries has over 15 years of R&D and translational research experience in biotechnology and therapeutics/biologics. He is a co-founder of AbCellera Biologics, having led AbCellera’s business development activities and key strategic partnerships with biopharmas, biotechs, and VCs, managing program design, negotiations, and alliances for several years. Prior to his departure from AbCellera in 2022, Dr Heyries launched a new group at AbCellera as Director of Emerging Science and Technology. More recently, Dr Heyries was Chief Business Officer of Inceptive Nucleics, a Palo Alto based mRNA/AI biotech backed by a16z, NVentures, Obvious ventures, among others.
Before co-founding AbCellera, Kevin was conducting post-doctoral research at the University of British Columbia where he focused on the development of high-sensitivity microfluidic digital PCR for genetic testing devices that was the basis for a commercial product. Kevin has a PhD in Biochemistry from the University of Lyon and an MSc in Organic Chemistry/Biology from the University of Grenoble.
Dr. Heyries is a TEDx 2018 speaker, and has been the recipient of the Top 40 under 40 in Vancouver (2020), and Top 30 under 40 young leaders transforming healthcare, Business Insider 2020 list. Outside work, his interests are focused on backcountry skiing, ski racing (CSC coach), scuba diving, mountain biking and long distance trail running.